New Oriental Education & Technology Group Inc. (EDU) Reaches $90.09 Formed H&S; 2 Analysts Bullish Silence Therapeutics plc (LON:SLN)

Silence Therapeutics plc (LON:SLN) Logo

New Oriental Education & Technology Group Inc. (EDU) formed H&S with $87.39 target or 3.00% below today’s $90.09 share price. New Oriental Education & Technology Group Inc. (EDU) has $14.25B valuation. The stock decreased 0.22% or $0.2 during the last trading session, reaching $90.09. About 681,904 shares traded. New Oriental Education & Technology Group Inc. (NYSE:EDU) has risen 50.87% since April 30, 2017 and is uptrending. It has outperformed by 39.32% the S&P500.

Among 2 analysts covering Silence Therapeutics PLC (LON:SLN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Silence Therapeutics PLC had 12 analyst reports since September 29, 2015 according to SRatingsIntel. As per Thursday, February 1, the company rating was maintained by Peel Hunt. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, August 11. The stock has “Buy” rating by Peel Hunt on Tuesday, April 3. The stock of Silence Therapeutics plc (LON:SLN) earned “Buy” rating by Peel Hunt on Monday, March 26. The stock of Silence Therapeutics plc (LON:SLN) has “Buy” rating given on Tuesday, September 27 by Canaccord Genuity. The rating was maintained by Peel Hunt with “Buy” on Monday, January 8. The rating was maintained by Peel Hunt with “Buy” on Thursday, December 28. Peel Hunt maintained Silence Therapeutics plc (LON:SLN) rating on Monday, January 22. Peel Hunt has “Buy” rating and GBX 275 target. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, December 20 report. The stock of Silence Therapeutics plc (LON:SLN) has “Buy” rating given on Monday, January 9 by Canaccord Genuity. See Silence Therapeutics plc (LON:SLN) latest ratings:

03/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 277.00 Maintain
26/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 277.00 New Target: GBX 277.00 Maintain
01/02/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
22/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
08/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 276.00 New Target: GBX 276.00 Maintain
28/12/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain
14/12/2017 Broker: Peel Hunt Rating: Buy New Target: GBX 276.00 Initiates Starts

Among 12 analysts covering New Oriental Education & Technology Group (NYSE:EDU), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. New Oriental Education & Technology Group has $116 highest and $27 lowest target. $73.91’s average target is -17.96% below currents $90.09 stock price. New Oriental Education & Technology Group had 37 analyst reports since September 9, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, January 18 by JP Morgan. TH Capital maintained it with “Buy” rating and $52 target in Thursday, July 21 report. Jefferies maintained New Oriental Education & Technology Group Inc. (NYSE:EDU) rating on Sunday, August 27. Jefferies has “Buy” rating and $93.5 target. The company was initiated on Friday, August 25 by Morgan Stanley. The firm has “Neutral” rating given on Thursday, July 21 by Nomura. The stock of New Oriental Education & Technology Group Inc. (NYSE:EDU) has “Buy” rating given on Wednesday, January 24 by Jefferies. Brean Capital upgraded the stock to “Buy” rating in Wednesday, October 21 report. The rating was upgraded by JP Morgan on Monday, March 5 to “Neutral”. The firm has “Buy” rating by TH Capital given on Monday, January 18. The stock of New Oriental Education & Technology Group Inc. (NYSE:EDU) earned “Buy” rating by Jefferies on Tuesday, April 24.

Silence Therapeutics plc focuses on the discovery, development, and delivery of RNA therapeutics. The company has market cap of 114.21 million GBP. The firm creates short interfering RNA molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It currently has negative earnings. It is developing Atu027, a drug candidate that is in Phase IIa study for use in the treatment of pancreatic cancer, as well as various GalNAc-siRNA candidates for use in the treatment of iron overload disorders, acromegaly, cardiovascular disease, alcohol use disorder, and other metabolic diseases.

The stock decreased 2.40% or GBX 4 during the last trading session, reaching GBX 163. About 16 shares traded. Silence Therapeutics plc (LON:SLN) has 0.00% since April 30, 2017 and is . It has underperformed by 11.55% the S&P500.

New Oriental Education & Technology Group Inc. (NYSE:EDU) Ratings Chart